Chemotherapy and Other Systemic Therapies for Hepatocellular Carcinoma and Liver Metastases

Kevin S. Brown

doi:10.1055/s-2006-939845

Seminars in Interventional Radiology, Inhaltsverzeichnis

Semin intervent Radiol 2006; 23(1): 099-108
DOI: 10.1055/s-2006-939845

Chemotherapy and Other Systemic Therapies for Hepatocellular Carcinoma and Liver Metastases

Kevin S. Brown¹

¹Assistant Professor of Medicine, Denver Health Medical Center, University of Colorado Health Sciences Center, Department of Medicine, Division of Medical Oncology, Denver, Colorado

Abstract

ABSTRACT

For hepatocellular carcinoma (HCC) that has advanced to the point that it is no longer amenable to local therapies, systemic therapy can be considered in select patients who have a good performance status. No systemic therapy has been clearly shown to improve overall survival compared with supportive care alone, although cancer-related symptoms can sometimes be palliated with therapy and some objective responses are seen. Systemic therapies for HCC include chemotherapy, both intravenous and infused via the hepatic artery, as well as hormonal therapy, immunotherapy, and targeted biologic agents. Colorectal, pancreatic, breast, and lung cancer are some of the most common tumors that metastasize to the liver. Response rates and effect on overall survival as a result of systemic therapy for liver metastases vary widely depending on primary tumor site. Targeted biologic agents are being integrated into standard treatment regimens for all of these cancer types, with variable effects on survival and other outcomes for all affected patients including those with liver metastases.

KEYWORDS

Hepatocellular carcinoma - chemotherapy - systemic therapy - liver metastases

Volltext

Referenzen

REFERENCES

1 Park J G, Lee S K, Hong I G et al.. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst. 1994; 86 700-705
2 Park N H, Chung Y H, Youn K H et al.. Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma. J Clin Gastroenterol. 2001; 33 397-401
3 Valle J W, Dangoor A, Beech J et al.. Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin: results of a phase II study. Br J Cancer. 2005; 92 628-630
4 Hochster H S, Greeni M D, Speyer J et al.. 4′-Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol. 1985; 3 1535-1540
5 Pohl J, Zuna I, Stremmel W et al.. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy. 2001; 47 359-365
6 Dunk A A, Scott S C, Johnson P J et al.. Mitozantrone as single agent therapy in hepatocellular carcinoma: a phase II study. J Hepatol. 1985; 1 395-404
7 Colleoni M, Nole F, Di Bartolomeo M et al.. Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. Oncology. 1992; 49 139-142
8 Tetef M, Doroshow J, Akman S et al.. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest. 1995; 13 460-463
9 Link J S, Bateman J R, Paroly W S et al.. 5-Fluorouracil in hepatocellular carcinoma: report of twenty-one cases. Cancer. 1977; 39 1936-1939
10 Porta C, Moroni M, Nastasi G et al.. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Oncology. 1995; 52 487-491
11 Lozano R D, Patt Y Z, Hassan M M et al.. Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer) (abstract 1025). Paper presented at Annual Meeting of the American Society of Clinical Oncology. May 20-23, 2000 New Orleans, LA;
12 Okada S, Okazaki N, Nose H et al.. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology. 1993; 50 22-26
13 Shin D, Lee S, Park J et al.. Systemic chemotherapy with capecitabine, doxorubicin and cisplatin for metastatic hepatocellular carcinoma (abstract 4177). Paper presented at Annual Meeting of the American Society of Clinical Oncology. May 13-17, 2005 Orlando, FL;
14 Lee J, Park J O, Kim W S et al.. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol. 2004; 54 385-390
15 Yang T S, Chang W C, Lin Y C et al.. A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma (abstract 1351). Paper presented at Annual Meeting of the American Society of Clinical Oncology. May 31-June 3, 2003 Chicago, IL;
16 Ikeda M, Okusaka T, Ueno H et al.. A phase II trial of continuous-infusion 5-fluorouracil, mitoxantrone and cisplatin for metastatic hepatocellular carcinoma (abstract 4081). Paper presented at Annual Meeting of the American Society of Clinical Oncology. June 5-8, 2004 New Orleans, LA;
17 Kim G P, Alberts S R, Tschetter L K et al.. Gemcitabine andaocetaxel in patients with measurable unresectable or metastatic hepatocellular carcinoma, a North Central Cancer Treatment Group (NCCTG) phase II trial (abstract 4270). Paper presented at Annual Meeting of the-American Society of Clinical Oncology. June 5-8, 2004 New Orleans, LA;
18 Kemeny N, Kemeny M, Lawrence T S. Liver metastases. In: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG Clinical Oncology. Philadelphia; Elsevier Churchill Livingstone 2004: 1141-1178
19 Jang B K, Kwon K M, Chung W J et al.. Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil and cisplatin. Korean J Hepatol. 2004; 10 271-278
20 Lin C P, Yu H C, Cheng J S et al.. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-fluorouracil for unresectable advanced hepatocellular carcinoma. J Chin Med Assoc. 2004; 67 602-610
21 Ru J, Byone S, Nelson T et al.. Hepatic intra-arterial infusion (HIA) of cisplatin and mitomycin-C for hepatocellular carcinoma: the USC experience (abstract 1519). Paper presented at: Annual Meeting of the American Society of Clinical Oncology. May 31-June 3, 2003 Chicago, IL;
22 Jonas S, Bechstein W O, Heinze T et al.. Female sex hormone receptor status in advanced hepatocellular carcinoma and outcome after surgical resection. Surgery. 1997; 121 456-461
23 Villa E, Colantoni A, Grottola A et al.. Variant estrogen receptors and their role in liver disease. Mol Cell Endocrinol. 2002; 193 65-69
24 Chow P K, Tai B C, Tan C K et al.. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology. 2002; 36 1221-226
25 Perrone F, Gallo C, Daniele B et al.. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multi-centre randomized controlled trial. Curr Pharm Des. 2002; 8 1013-1019
26 Villa E, Ferretti I, Grottola A et al.. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer. 2001; 84 881-885
27 Negro F, Papotti M, Pacchioni D et al.. Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridization. Liver. 1994; 14 213-219
28 Grimaldi C, Bleiberg H, Gay F et al.. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol. 1998; 16 411-417
29 Manesis E K, Giannoulis G, Zoumboulis P et al.. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology. 1995; 21 1535-1542
30 Reubi J C, Zimmermann A, Jonas S et al.. Regulatory peptide receptors in human hepatocellular carcinomas. Gut. 1999; 45 766-774
31 Kouroumalis E, Skordilis P, Thermos K et al.. Treatment of hepatocellular carcinoma with octreotide: - randomised controlled study. Gut. 1998; 42 442-447
32 Yuen M F, Poon R T, Lai C L et al.. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. 2002; 36 687-691
33 Radaeva S, Jaruga B, Hong F et al.. Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology. 2002; 122 1020-1034
34 Llovet J M, Sala M, Castells L et al.. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000; 31 54-58
35 Ji S K, Park N H, Choi H M et al.. Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma. Korean J Intern Med. 1996; 11 56-68
36 Yeo W, Zee B, Leung W T et al.. A phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil combination chemotherapy for inoperable hepatocellular carcinoma (abstract 4026). Paper presented at Annual Meeting of the American Society of Clinical Oncology. June 5-8, 2004 New Orleans, LA;
37 Vacca A, Ribatti D, Roncali L et al.. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994; 87 503-508
38 Rajkumar S V, Fonseca R, Witzig T E et al.. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia. 1999; 13 469-472
39 Argiles J M, Carbo N, Lopez-Soriano F J et al.. Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s?. Med Hypotheses. 1998; 50 313-318
40 Patt Y Z, Hassan M M, Lozano R D et al.. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 2005; 103 749-755
41 Zhu A X, Fuchs C S, Clark J W et al.. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005; 10 392-398
42 Lersch C, Schmelz R, Erdmann J et al.. Treatment of HCC with pravastatin, octreotide, or gemcitabine: a critical evaluation. Hepatogastroenterology. 2004; 51 1099-1103
43 Benson III A B, Schrag D, Somerfield M R et al.. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004; 22 3408-3419
44 Fernandez F G, Drebin J A, Linehan D C et al.. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with fluorodeoxyglucose (FDG-PET). Ann Surg. 2004; 240 438-447
45 Gruenberger T, Schuell B, Kornek G et al.. Elderly patients do benefit from oxaliplatin based neoadjuvant chemotherapy in resectable colorectal cancer liver metastases (abstract 3601). Paper presented at Annual Meeting of the American Society of Clinical Oncology. May 13-17, 2005 Orlando, FL;
46 Bathe O F, Ernst S, Sutherland F et al.. A phase II study of neoadjuvant irinotecan, 5-fluorouracil and leucovorin for resectable liver metastases from colorectal cancer (abstract 3662). Paper presented at Annual Meeting of the American Society of Clinical Oncology. May 13-17, 2005 Orlando, FL;
47 Saltz L B, Cox J V, Blanke C et al.. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000; 343 905-964
48 Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998; 16 301-308
49 Douillard J Y, Cunningham D, Roth A D et al.. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet. 2000; 355 1041-1047
50 Goldberg R M, Sargent D J, Morton R F et al.. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22 23-30
51 Twelves C. Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer. 2002; 38 S15-S20
52 Cassidy J, Tabernero J, Twelves C et al.. XELOX (capecitabine plus oxaiiplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004; 22 2084-2091
53 Grothey A, Jordan K, Kellner O et al.. Randomized phase II trial of capecitabine plus irinotecan versus capecitabine plus oxaliplatin as first-line therapy of advanced colorectal cancer (abstract 1022). Paper presented at Annual Meeting of the American Society of Clinical Oncology. May 31-June 3, 2003 Chicago, IL;
54 Cunningham D, Humblet Y, Siena S et al.. Cetuximab monotherapy and - cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351 337-345
55 Susman E. Rash correlates with tumour response after cetuximab. Lancet Oncol. 2004; 5 647
56 Hurwitz H, Fehrenbacher L, Novotny W et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350 2335-2342
57 Giantonio B J, Catalano P J, Meropol N J et al.. High-dose bevacizumab improves survival when combined with FOLFOX-4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200 (abstract 2). Paper presented at Annual Meeting of the American Society of Clinical Oncology. May 13-17, 2005 Orlando, FL;
58 Lenz H-J, Hochster H, Wadler S et al.. Randomized phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer (abstract 3508). Paper presented at Annual Meeting of the American Society of Clinical Oncology. May 13-17, 2005 Orlando, FL;
59 Breedis C, Young C. The blood supply of neoplasms in the liver. Am J Pathol. 1954; 30 969-985
60 Hohn D, Stagg R, Friedman M et al.. A randomized trial of continuous intravenous versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group Trial. J Clin Oncol. 1989; 7 1646-1654
61 Chang A E, Schneider P D, Sugarbaker P H et al.. A prospective randomized trial of regional versus systemic continuous 5-fluoroxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987; 206 685-693
62 Martin J KJ, O'Connell M G, Wieland H S et al.. Intra-arterial floxuridine versus systemic fluorouracil for hepatic metastases from colorectal cancer a randomized trial. Arch Surg. 1990; 125 1022-1027
63 Kemeny N, Kemeny M, Lawrence T. Liver metastases. In: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna W Clinical Oncology. Philadelphia; Elsevier Churchill Livingstone 2004: 1141-1178
64 Muss H B, Case L D, Atkins J N et al.. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol. 1994; 12 1630-1638
65 Manni A, Trujillo J E, Marshall J S et al.. Antihormone treatment of stage IV breast cancer. Cancer. 1979; 43 444-450
66 Nabholtz J M, Buzdar A, Poltak M et al.. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol. 2000; 18 3758-3757
67 Bonneterre J, Thurlimann B, Robertson J F et al.. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol. 2000; 18 3748-3757
68 Mouridsen H, Gershanovich M, Sun Y et al.. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001; 19 2596-2606
69 Nabholtz J M, Mackey J R, Smylie M et al.. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol. 2001; 19 314-321
70 Sledge G W, Neuberg D, Bernardo P et al.. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003; 21 588-592
71 Vogel C L, Cobleigh M A, Tripathy D et al.. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20 719-726
72 Slamon D J, Leyland-Jones B, Shak S et al.. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344 783-792
73 Fraschini G, Fleishman G, Yap H-Y et al.. Percutaneous hepatic arterial infusion of cisplatin for metastatic breast cancer. Cancer Treat Rep. 1987; 71 313-315
74 Arai Y, Sone Y, Inaba Y et al.. Hepatic arterial infusion chemotherapy forlrver metastases from breast cancer. Cancer Chemother Pharmacol. 1994; 33(suppl) 142-144
75 Noda K, Nishiwaki Y, Kawahara M et al.. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med. 2002; 346 85-91
76 Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first; line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist. 2001; 6(suppl 1) 4-7
77 Gridelli C, Aapro M, Ardizzoni A et al.. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol. 2005; 23 3125-3137
78 Sandier A B, Gray R, Brahmer J et al.. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncology Group trial-E4599 (abstract LBA4). Paper presented at Annual Meeting of the American Society of Clinical Oncology. May 13-17, 2005 Orlando, FL;
79 Shepherd F A, Pereira J, Ciuleanu T E et al.. A randomized placebo-cohlrolled trial of erlotinib in patients with advanced non-small cell lung cancer following failure of first or second line chemotherapy: a National Cancer Institute of Canada Clinical Trials Group trial (abstract 7022). Paper presented at Annual Meeting of the American Society of Clinical Oncology. June 5-8, 2004 New Orleans, LA;
80 Bums III H A, Moore M J, Andersen J et al.. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: arandomized trial. J Clin Oncol. 1997; 15 2403-2413
81 Moore M J, Goldstein D, Hamm J et al.. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group (abstract 1). Paper presented at Annual Meeting of the American Society of Clinical Oncology. May 13-17, 2005 Orlando, FL;

Kevin S. BrownM.D.

660 Bannock Street, Mail Code 4000, Denver, CO 80204